Delving into the Latest Updates on Sildenaifl Citrate with Synapse

Overview

Basic Info

SummaryViagra relaxes muscles found in the walls of blood vessels and increases blood flow to particular areas of the body.Viagra is used to treat erectile dysfunction (impotence) in men. Another brand of sildenafil is Revatio, which is used to treat pulmonary arterial hypertension and improve exercise capacity in men and women. This page contains specific information for Viagra, not Revatio. Sildenafil acts by blocking phosphodiesterase 5 (PDE5), an enzyme that promotes breakdown of cGMP, which regulates blood flow in the penis. It requires sexual arousal to work. It also results in dilation of the blood vessels in the lungs. Pfizer originally discovered the medication in 1989 while looking for a treatment for heart-related chest pain. It was approved for medical use in the United States and in the European Union in 1998.

Drug Type

Small molecule drug

Synonyms

Pahtension, Revatio, Revatio OD

+ [46]

Target

PDE5A

Action

inhibitors

Mechanism

PDE5A inhibitors(Phosphodiesterase 5A inhibitors)

Therapeutic Areas

Respiratory DiseasesUrogenital DiseasesOther Diseases+ [5]

Active Indication

Idiopathic pulmonary arterial hypertensionHypertension, PulmonaryFamilial Primary Pulmonary Hypertension+ [9]

Inactive Indication

Chronic heart failureDigital ulcerGangliosidosis, GM1+ [20]

Originator Organization

Pfizer Inc.

Active Organization

Viatris, Inc.Upjohn EESVViatris Pty Ltd.

+ [21]

Inactive Organization

Pfizer Inc.

iX Biopharma Ltd.

Kyukyu Pharmaceutical Co., Ltd.

+ [1]

License Organization

Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Daré Bioscience, Inc.

Aspargo Labs, Inc.

+ [9]

Drug Highest PhaseApproved

First Approval Date

United States (27 Mar 1998),

Erectile Dysfunction

RegulationOrphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan), Orphan Drug (South Korea), Overseas New Drugs Urgently Needed in Clinical Settings (China), Priority Review (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC28H38N6O11S

InChIKeyDEIYFTQMQPDXOT-UHFFFAOYSA-N

CAS Registry171599-83-0

The main objective of this study is to assess pharmacokinetics features of IV sildenafil in neonates with hypoxic-ischemic encephalopathy and treated by controlled hypothermia. This phase 2 study will prepare a large phase 3 randomized controlled trial to demonstrate the superiority of a combinatory therapy associating IV sildenafil and controlled hypothermia compared to Placebo and controlled hypothermia, on survival without brain lesions on MRI at discharge, in neonates born after 36 weeks of gestation.

Start Date01 Oct 2026

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

NCT07290400

/ Not yet recruitingPhase 2

Phase 2 Crossover Study Assessing the Effect of Moderate Alcohol Intake on the Absorption and Onset of Action of Hezkue® Sildenafil Oral Suspension

This is a Phase 2, open-label, randomized crossover study assessing the effect of moderate alcohol intake on the absorption and onset of action of Hezkue® sildenafil oral suspension in adult subjects. Participants will receive Hezkue® under different alcohol intake conditions in randomized sequence. Pharmacokinetic sampling and onset assessments will be performed after each administration, and safety will be monitored throughout the study.

Start Date15 Apr 2026

Sponsor / Collaborator

Aspargo Labs, Inc.

NCT06800092

/ Not yet recruitingPhase 2/3IIT

Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment

This study is examining the effects of standard of care cancer treatment as well as a medication called Sildenafil, on the cancer associated fatigue, cognition and the gut microbiome.

Start Date15 Mar 2026

Sponsor / Collaborator

University of Texas Medical Branch

100 Clinical Results associated with Sildenaifl Citrate

Login to view more data

100 Translational Medicine associated with Sildenaifl Citrate

Login to view more data

100 Patents (Medical) associated with Sildenaifl Citrate

Login to view more data

8,851

Literatures (Medical) associated with Sildenaifl Citrate

01 Mar 2026·PEDIATRIC NEPHROLOGY

From RAAS blockade to regenerative medicine: evolving treatment strategies in Alport syndrome

Review

Author: Kim, Jin-Ju ; Lo Re, Claudia ; Fornoni, Alessia

Abstract:

Alport syndrome (AS) is a hereditary glomerulopathy caused by mutations in the COL4A3 , COL4A4 , or COL4A5 genes, leading to progressive kidney decline and extrarenal manifestations. Advances in genetic testing have enabled the reclassification of AS into X-linked, autosomal recessive, and autosomal dominant forms, facilitating more accurate diagnosis and risk stratification. While renin-angiotensin-aldosterone system (RAAS) blockade remains the foundation of treatment to delay kidney failure, it does not directly target the underlying molecular pathology. Adjunctive commercially available metabolic modulators, including SGLT2i, mineralocorticoid receptor antagonists, ezetimibe and GLP-1 receptor agonists, may offer additional kidney protection. Ameliorating therapies being tested in Phase II trials include endothelin receptor antagonists (e.g., atrasentan), dual endothelin receptor antagonist and angiotensin II receptor inhibition (e.g., sparsentan) FXR agonists (e.g., vonafexor), inducers of cholesterol efflux (e.g., VAR200 and R3R01), and NOX1/4 inhibitors (e.g., setanaxib), several of which are currently being evaluated in clinical trials. Novel strategies such as exon skipping, gene editing, and nonsense mutation readthrough (e.g., ELX-02) are advancing toward precision medicine approaches as disease modifying agents targeting the genetic cause of AS. Moreover, therapies targeting mitochondrial function, such as mitophagy enhancers, have demonstrated preclinical promise. Stem cell-based approaches are also being explored for their regenerative and anti-fibrotic effects. This review summarizes the current landscape of AS classification and treatment, highlighting both standard interventions and experimental therapies. Emphasis is placed on the molecular mechanisms underlying podocyte injury and fibrosis, recent preclinical findings, and ongoing clinical trials that may shift future therapeutic paradigms. Graphical abstract

07 Feb 2026·JOURNAL OF DRUG TARGETING

Comparison of a poloxamer-based thermally sensitive gel and an HPMC-based standard gel used to increase sildenafil citrate retention in the uterus

Article

Author: Zhang, Qing ; Tang, Jingling ; Ren, Jinmei ; Zhang, Chenghao ; Cui, Xinran ; Liu, Jiaxin ; Wu, Zhaoli ; Wang, Shuxia

OBJECTIVE:

Sildenafil citrate (SC) could promote uterine lining development, leading to successful embryo implantation. Due to the low oral bioavailability of the first-pass elimination of SC, it is necessary to develop a gel for vaginal administration to improve the efficacy.

METHODS:

A vaginal gel was prepared using the cold method to increase the retention of SC in the uterus, which allows for prolonged contact between SC and the vaginal mucosa. A poloxamer-based thermosensitive in situ gel containing SC (SC-Tsgel) and an HPMC-based standard gel containing SC (SC-Cogel) were prepared. The rheological properties, in vitro drug release, and in vivo retention in the uterus of SC-Tsgel and SC-Cogel were compared.

RESULTS:

The gel formulations significantly prolonged the time it took for drugs to be released following a release study. SC-Tsgel and SC-Cogel administered vaginally increased the duration of drug administration compared to SC solutions injected through the tail vein. Nevertheless, compared with tail vein injection of SC solutions or vaginal administration of the SC-Cogel, the retention of SC in the uterus was increased significantly after vaginal administration of the SC-Tsgel.

CONCLUSIONS:

Novel formulations of SC prepared with poloxamer 407 show promise as vaginal medication preparations for the management of a thin endometrium.

01 Feb 2026·JOURNAL OF ETHNOPHARMACOLOGY

In vivo aphrodisiac efficacy of aqueous and hydroalcoholic extracts of the leaf and root bark of Citropsis articulata (Willd. ex Spreng.) Swingle & M.Kellerm. in male Wistar rats

Article

Author: Tusiimire, Jonans ; Ogwang, Patrick Engeu ; Angupale, Jimmy Ronald ; Amito, Vivian Sharon ; Ajayi, Clement Olusoji ; Amaza, Ronald Anyase ; Amutuhaire, Treasure Angie ; Abdelgadir, Abdelgadir Alamin ; Anywar, Godwin

ETHNOPHARMACOLOGICAL RELEVANCE:

Citropsis articulata (Willd. ex Spreng.) Swingle & M.Kellerm (Rutaceae), commonly known as the African cherry orange, is traditionally used to enhance male sexual performance and manage erectile dysfunction in various African communities.

AIM OF THE STUDY:

This study aimed to evaluate the aphrodisiac efficacy of the aqueous and hydroalcoholic extracts of C. articulata leaf and root bark in male Wistar rats.

MATERIALS AND METHODS:

Aqueous extracts (decoctions) were prepared by boiling 500 g of dried herbal powder in 4 L of distilled water for 60 min. Hydroalcoholic extracts were obtained by Soxhlet extraction, where 500 g of the powder was continuously percolated with 2.5 L of 70 % ethanol. Male Wistar rats (n = 6 per group) were administered the extracts at doses of 100, 500, and 1000 mg/kg daily for 28 days. Control groups included two negative controls (distilled water and 10% DMSO + 0.1% gum arabic) and a positive control (sildenafil citrate, 5 mg/kg). Sexual behaviour parameters-including attraction to the female, penile erection, mount frequency, and mount latency-were assessed on days 0, 3, 7, 14, 21, and 28. At day 28, three animals per group were sacrificed for evaluation of testosterone levels, sexual organ weights, and histological analysis. The remaining three animals in each group were observed without further dosing for an additional 14 days, with behavioural assessments on days 35 and 42, before being sacrificed for post-treatment evaluation of sustained or delayed effects.

RESULTS:

Both the root bark and leaf extracts of C. articulata significantly enhanced attraction towards the female, penile erection, and mount frequency, while reducing mount latency in male Wistar rats. The leaf extracts exhibited a slightly stronger aphrodisiac effect compared to the root bark, especially at the 500 mg/kg dose, where the leaf decoction produced a greater increase in testosterone levels and more pronounced improvements in sexual behaviour. Notably, administration of the leaf decoction at 500 mg/kg resulted in a significantly higher testosterone level (14.50 ± 2.53 ng/ml) compared to the positive control (sildenafil citrate, 4.00 ± 2.70 ng/ml; p = 0.021, 95 % CI: -19.45 to -1.533). After 28 days of treatment, testosterone levels were elevated across all extract-treated groups but declined markedly in animals monitored for an additional 14 days without dosing. Histological analysis showed active spermatogenesis during treatment, which diminished following cessation of extract administration.

CONCLUSION:

This study revealed that both the root bark and leaf of C. articulata have aphrodisiac efficacy in male Wistar rats in vivo.

266

News (Medical) associated with Sildenaifl Citrate

18 Feb 2026

·www.sciencedaily.com

Viagra and shingles vaccine show surprising promise against Alzheimer’s

A major new study has spotlighted three familiar medicines that could take on an unexpected new role in the fight against Alzheimer’s disease — with a shingles vaccine emerging as the front-runner. After reviewing 80 existing drugs, an international panel of experts identified Zostavax, Viagra (sildenafil), and riluzole as the most promising candidates for repurposing.Researchers have pinpointed three already approved medications that may be repurposed to treat or prevent Alzheimer's disease. Instead of starting from scratch, scientists examined medicines that are currently used for other conditions to see whether any could help protect the brain. The study, funded by Alzheimer's Society and led by the University of Exeter, was published in Alzheimer's Research and Therapy. Among the drugs reviewed, a shingles vaccine (Zostavax) emerged as the most promising candidate. Viagra (sildenafil) and a medication used to treat motor neurone disease (riluzole) also showed strong potential. Why Drug Repurposing Matters Dementia is the leading cause of death in the UK, affecting around one million people. One in three people born today will develop dementia in their lifetime -- yet there is still no cure. Creating brand new drugs can take 10 to 15 years and cost billions of pounds -- with no guarantee of success. Repurposing medicines that are already approved and widely used could provide a faster, safer, and more affordable path toward new Alzheimer's treatments. This work was also supported by the National Institute for Health and Care Research (NIHR), the Exeter Biomedical Research Centre, and the NIHR HealthTech Research Centre in Brain Health. How the Top Alzheimer's Candidates Were Chosen An international group of 21 dementia specialists from universities, hospitals, and the pharmaceutical industry, along with people affected by dementia, evaluated 80 existing medications. Their goal was to identify which ones showed the greatest promise for treating or preventing Alzheimer's disease, which accounts for more than half of all dementia diagnoses. After multiple rounds of review, the panel agreed on three 'priority candidates' for further research. Each drug was selected because it targets biological processes linked to Alzheimer's, has shown encouraging results in cell and animal studies, and is considered safe for use in older adults. The three priority drugs are: Shingles Vaccine Shows Strongest Signal Experts are now calling for clinical trials to determine whether these medications truly benefit people who have Alzheimer's or are at risk of developing it. Among the three, the shingles vaccine stood out. It requires no more than two doses and has a long record of safety. Previous research suggests that people who received the vaccine were about 16% less likely to develop dementia. Researchers hope to launch a large UK clinical trial of the shingles vaccine, using the to track participants. PROTECT is an online registry in which volunteers complete annual questionnaires about their health and lifestyle and take part in brain health research. Other Drugs Considered Five additional medications were shortlisted but did not meet the criteria to be named 'priority candidates.' These included fingolimod (used in MS), vortioxetine (used to treat major depressive disorder), microlithium (used to treat depression), dasitinib (used for leukaemia), and cytisine (used in anesthetics). Experts Urge Caution and Further Trials Dr. Anne Corbett, Professor of Dementia Research at the University of Exeter, said: "Beating dementia will take every avenue of research -- from using what we already know, to discovering new drugs to treat and prevent the condition. "Drug repurposing is a vital part of that mix, helping us turn today's medicine for one condition, into tomorrow's treatment for another. "It's important to stress that these drugs need further investigation before we will know whether they can be used to treat or prevent Alzheimer's. We now need to see robust clinical trials to understand their true value and know for certain if they are effective to treat or prevent Alzheimer's." Prof Fiona Carragher, Chief Policy and Research Officer at Alzheimer's Society, said: "Dementia devastates lives, but we believe research will beat it. "Years ago, we saw aspirin being repurposed from being a painkiller to helping people reduce their risk of heart attack or stroke. This is what we want to see in the field of dementia, and why we believe drug repurposing is one of the most exciting frontiers in dementia research."

Vaccine

13 Feb 2026

·www.einpresswire.com

Fantasy Aphrodisiac Chocolate may be harmful due to hidden drug ingredient

[2-13-2026] The Food and Drug Administration is advising consumers not to purchase or use Fantasy Aphrodisiac Chocolate, a product promoted and sold for sexual enhancement on various websites, including gearisle.com, and possibly in some retail stores. FDA laboratory analysis confirmed that Fantasy Aphrodisiac Chocolate contains sildenafil not listed on the product label. Sildenafil is the active ingredient in the FDA-approved prescription drug Viagra, used to treat erectile dysfunction. FDA approval of Viagra is restricted to use under the supervision of a licensed health care professional. This undeclared ingredient may interact with nitrates found in some prescription drugs, such as nitroglycerin, and may lower blood pressure to dangerous levels. People with diabetes, high blood pressure, high cholesterol or heart disease often take nitrates. Health care professionals and consumers should report adverse events or side effects related to the use of this product to FDA’s MedWatch Safety Information and Adverse Event Reporting Program: This notification is to inform the public of products potentially marketed as dietary supplements or conventional foods with hidden drug ingredients and chemicals. These products are typically promoted for sexual enhancement, weight loss, pain relief and body building and are often represented as being all natural. Consumers should exercise caution before purchasing these products. FDA is unable to test and identify all products marketed as dietary supplements that have potentially harmful hidden ingredients. Refer to the links below for more information: Content current as of: 02/13/2026 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

13 Feb 2026

·www.einpresswire.com

Boner Bears Chocolate may be harmful due to hidden drug ingredient

[2-13-2026] The Food and Drug Administration is advising consumers not to purchase or use Boner Bears Chocolate, a product promoted and sold for sexual enhancement on various websites, including lockoutsupplements.com, and possibly in some retail stores. FDA laboratory analysis confirmed that Boner Bears Chocolate contains sildenafil not listed on the product label. Sildenafil is the active ingredient in the FDA-approved prescription drug Viagra, used to treat erectile dysfunction. FDA approval of Viagra is restricted to use under the supervision of a licensed health care professional. This undeclared ingredient may interact with nitrates found in some prescription drugs, such as nitroglycerin, and may lower blood pressure to dangerous levels. People with diabetes, high blood pressure, high cholesterol or heart disease often take nitrates. Health care professionals and consumers should report adverse events or side effects related to the use of this product to FDA’s MedWatch Safety Information and Adverse Event Reporting Program: This notification is to inform the public of products potentially marketed as dietary supplements or conventional foods with hidden drug ingredients and chemicals. These products are typically promoted for sexual enhancement, weight loss, pain relief and body building and are often represented as being all natural. Consumers should exercise caution before purchasing these products. FDA is unable to test and identify all products marketed as dietary supplements that have potentially harmful hidden ingredients. Refer to the links below for more information: Content current as of: 02/13/2026 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 Deals associated with Sildenaifl Citrate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02229	Sildenaifl Citrate	G04BE03	DB00203

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Idiopathic pulmonary arterial hypertension	European Union	Viatris, Inc.	15 Sep 2016
Idiopathic pulmonary arterial hypertension	Iceland	Viatris, Inc.	15 Sep 2016
Idiopathic pulmonary arterial hypertension	Liechtenstein	Viatris, Inc.	15 Sep 2016
Idiopathic pulmonary arterial hypertension	Norway	Viatris, Inc.	15 Sep 2016
Hypertension, Pulmonary	Japan	Viatris Pharmaceutical GK	25 Jan 2008
Familial Primary Pulmonary Hypertension	European Union	Upjohn EESV	28 Oct 2005
Familial Primary Pulmonary Hypertension	Iceland	Upjohn EESV	28 Oct 2005
Familial Primary Pulmonary Hypertension	Liechtenstein	Upjohn EESV	28 Oct 2005
Familial Primary Pulmonary Hypertension	Norway	Upjohn EESV	28 Oct 2005
Pulmonary arterial hypertension associated with congenital heart disease	European Union	Upjohn EESV	28 Oct 2005
Pulmonary arterial hypertension associated with congenital heart disease	Iceland	Upjohn EESV	28 Oct 2005
Pulmonary arterial hypertension associated with congenital heart disease	Liechtenstein	Upjohn EESV	28 Oct 2005
Pulmonary arterial hypertension associated with congenital heart disease	Norway	Upjohn EESV	28 Oct 2005
Pulmonary arterial hypertension associated with connective tissue disease	European Union	Upjohn EESV	28 Oct 2005
Pulmonary arterial hypertension associated with connective tissue disease	Iceland	Upjohn EESV	28 Oct 2005
Pulmonary arterial hypertension associated with connective tissue disease	Liechtenstein	Upjohn EESV	28 Oct 2005
Pulmonary arterial hypertension associated with connective tissue disease	Norway	Upjohn EESV	28 Oct 2005
Pulmonary Arterial Hypertension	United States	Viatris Specialty LLC	03 Jun 2005
Erectile Dysfunction	United States	Viatris Specialty LLC	27 Mar 1998

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart Failure	Phase 3	Canada	Pfizer Inc.	12 Mar 2018
Gangliosidosis, GM1	Phase 3	Italy	-	08 Mar 2013
Pulmonary Disease, Chronic Obstructive	Phase 3	Italy	-	08 Mar 2013
Chronic heart failure	Phase 3	Israel	Pfizer Inc.	01 Mar 2013
Chronic heart failure	Phase 3	Italy	Pfizer Inc.	01 Mar 2013
Chronic heart failure	Phase 3	Norway	Pfizer Inc.	01 Mar 2013
Chronic heart failure	Phase 3	United Kingdom	Pfizer Inc.	01 Mar 2013
Hypoxic respiratory failure	Phase 3	Belgium	Pfizer Inc.	14 Nov 2012
Persistent Fetal Circulation Syndrome	Phase 3	Belgium	Pfizer Inc.	14 Nov 2012
Heart failure with normal ejection fraction	Phase 3	Netherlands	Pfizer Inc.	01 Oct 2011

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04447989 (SILDI-SAFE, CTgov)	Phase 2	Bronchopulmonary Dysplasia	125	sildenafil (Cohort 1, Sildenafil)	konztvsafi = vhzomffdye jrokjduejw (slzyuwlyvd, deedkeekrr - mbipiubdwy) View more	-	26 Jan 2026
				sildenafil (Cohort 2, Sildenafil)	konztvsafi = dkcfusmxen jrokjduejw (slzyuwlyvd, uifyfirgpo - fgtwbusnqr) View more
NCT04356716 (CTgov)	Phase 2	Age Related Macular Degeneration \| Ischemia \| Central Serous Chorioretinopathy ... View more	22	Ocular Coherence Tomography-Angiography (OCT-A)+sildenafil	yvlpsnngtj(kwsktznmvk) = yqktlzemvo iklddjeylw (wacpdirnav, 0.21) View more	-	04 Jul 2025
ATS2025	Not Applicable	Pulmonary Arterial Hypertension	-	Macitentan	tpezxmduga(fbagzasteu) = Macitentan and Bosentan had statistically significant ROR of deaths when compared to Ambrisentan johkfgbhtw (cljwqsigcx ) View more	-	16 May 2025
				Bosentan
NCT00972569 (NCT00972569, Pubmed \| Circ Heart Fail)	Phase 1/2	Heart Failure cGMP	67	Low-dose intravenous BNP (0.005 µg/kg per minute)	wrlzfcwerd(hudlqyjpnh) = fduevbevlk nsqzphxjcx (wygjyomyyn, -14.6% - +9.4%) View more	Negative	01 Dec 2024
				Combination BNP/PDEV inhibition with sildenafil (25 mg q12 hours)	wrlzfcwerd(hudlqyjpnh) = rglfaptnjy nsqzphxjcx (wygjyomyyn, -5.3% - +18.8%) View more
NCT04948151 (Literature) Manual	Phase 2	Sexual Dysfunctions, Psychological	193	sildenafil	zvvvzilhbp(smcbfwgyms) = ubqtlmxuao xvymhznodh (ymsmpcnddy ) View more	Positive	31 Jul 2024
				Placebo	zvvvzilhbp(smcbfwgyms) = hwhwsdejrh xvymhznodh (ymsmpcnddy ) View more
NCT03199612 (SToPClot, CTgov)	Early Phase 1	Thrombosis \| Hemolysis	20	Sildenafil (Sildenafil)	giqvjvxnlp(wiecxrbyvq) = yfyuvukrlq trmnchidba (mklofbeprk, arihudhnlq - gunkpqpfvy) View more	-	10 Jul 2024
				Placebo Oral Tablet (Placebo Oral Tablet)	giqvjvxnlp(wiecxrbyvq) = hckbxhuvxj trmnchidba (mklofbeprk, hdgtqjmexg - mcjzofszvk) View more
NCT03855332 (OxHARP Trial, Pubmed \| Circ Res)	Phase 2	Cerebral Small Vessel Diseases	75	Sildenafil 50 mg	yfkxoxzsrr(ookrjtflud) = deqyperkna bqyyrxzftz (djqoywilsj, 0.5 - 3.15) View more	Positive	05 Jul 2024
NCT02060487 (Pubmed \| Circulation) Manual	Phase 4	Pulmonary Arterial Hypertension	385	Sildenafil 80 mg TID	qbgzdyqlnz(bfwueajkvh): HR = 0.51 (95% CI, 0.22 - 1.21), P-Value = <0.001 View more	Non-inferior	18 Jun 2024
				Sildenafil 5 mg TID
NCT04948151 (Literature \| Pubmed \| Obstet Gynecol) Manual	Phase 2	Sexual Dysfunctions, Psychological	-	Sildenafil	pyjcvdxdny(plxdmiprym) = hnrcdrgjix dwahkxeozh (eithmryenx, 0.62)	Positive	18 Jun 2024
				Placebo	pyjcvdxdny(plxdmiprym) = uizbbwlvhc dwahkxeozh (eithmryenx, 0.04)
NCT02466802 (Pubmed) Manual	Phase 1	Advanced Malignant Solid Neoplasm PDE5 expression in tumor samples	29	Regorafenibsildenafil	iqgrxwqjwb(sqqvylijcx) = The most common toxicities included palmar-plantar erythrodysesthesia syndrome (20 patients, 69%) and hypophosphatemia (18 patients, 62%). tuftiqxhsu (qypeslcviw ) View more	Positive	08 Mar 2024